Literature DB >> 26680560

Edoxaban in patients with atrial fibrillation.

Alon Eisen1, Christian T Ruff2.   

Abstract

Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial that led to regulatory approval.

Entities:  

Keywords:  Novel oral anticoagulants; atrial fibrillation; edoxaban; factor xa inhibitor; non-vitamin K oral anticoagulants

Mesh：

Substances：

Year:  2016        PMID： 26680560      PMCID： PMC5942795          DOI： 10.1177/1753944715622130

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN： 1753-9447


  32 in total

1.  Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.

Authors:  J Steffel; R P Giugliano; E Braunwald; S A Murphy; D Atar; H Heidbuchel; A J Camm; E M Antman; C T Ruff
Journal:  Eur Heart J       Date:  2015-05-13       Impact factor: 29.983

2.  A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.

Authors:  Gregory Y H Lip; Jose Merino; Michael Ezekowitz; Kenneth Ellenbogen; Dmitry Zamoryakhin; Hans Lanz; James Jin; Naab Al-Saadi; Michele Mercuri; Andreas Goette
Journal:  Am Heart J       Date:  2015-02-21       Impact factor: 4.749

3.  Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

Authors:  Christian T Ruff; Robert P Giugliano; Elliott M Antman; Sharon E Crugnale; Tomas Bocanegra; Michele Mercuri; James Hanyok; Indravadan Patel; Minggao Shi; Dan Salazar; Carolyn H McCabe; Eugene Braunwald
Journal:  Am Heart J       Date:  2010-10       Impact factor: 4.749

Review 4.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

5.  Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.

Authors:  Giulia Magnani; Robert P Giugliano; Christian T Ruff; Sabina A Murphy; Francesco Nordio; Marco Metra; Tiziano Moccetti; Veselin Mitrovic; Minggao Shi; Michele Mercuri; Elliott M Antman; Eugene Braunwald
Journal:  Eur J Heart Fail       Date:  2016-06-28       Impact factor: 15.534

6.  Ex vivo reversal of the anticoagulant effects of edoxaban.

Authors:  Abdel-Baset Halim; Meyer M Samama; Jeanne Mendell
Journal:  Thromb Res       Date:  2014-08-07       Impact factor: 3.944

7.  End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.

Authors:  Kenneth W Mahaffey; Anne S Hellkamp; Manesh R Patel; Karen L Hannan; Kimberly Schwabe; Christopher C Nessel; Scott D Berkowitz; Jonathan L Halperin; Graeme J Hankey; Richard C Becker; Jonathan P Piccini; Günter Breithardt; Werner Hacke; Daniel E Singer; Robert M Califf; Keith A A Fox
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-06-11

8.  Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.

Authors:  Carla Rognoni; Monia Marchetti; Silvana Quaglini; Nicola Lucio Liberato
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

Review 9.  Antidotes for novel oral anticoagulants: current status and future potential.

Authors:  Mark Crowther; Mark A Crowther
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-18       Impact factor: 8.311

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245
View more
  1 in total

Review 1.  Direct oral anticoagulant considerations in solid organ transplantation: A review.

Authors:  David M Salerno; Demetra Tsapepas; Apostolos Papachristos; Jae-Hyung Chang; Spencer Martin; Mark A Hardy; Jaclyn McKeen
Journal:  Clin Transplant       Date:  2016-12-28       Impact factor: 2.863
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.